NEW YORK--(BUSINESS WIRE)--Wall Street is once again throwing its weight behind an important cause when the Leveraged Finance community comes together to help finance the fight to treat and cure melanoma, the most deadly form of skin cancer.
The Leveraged Finance Fights Melanoma (LFFM) networking and fundraising event is spearheaded by two of the Street’s melanoma survivors -- Jeff Rowbottom, KKR’s Head of Capital Markets in the Americas and a Melanoma Research Alliance (MRA) board member, and Brendan Dillon, UBS Managing Director, Global Leveraged Finance Syndicate and Financial Sponsors. This year will mark the third year of the annual event, which benefits the Melanoma Research Alliance, the largest private funder of melanoma research.
This year’s event will be held from 6:30-8:30 pm on Tuesday, May 20th at The Sea Grill and Summer Garden at Rockefeller Plaza. The event attracts leaders from throughout the industry and has raised more than $2 million for melanoma research since 2012. The host committee and attendees include professionals working in leveraged finance spanning all the top banks, investment houses, law firms, select issuers, and private equity sponsors.
All funds raised support MRA’s global research programs working toward eliminating suffering and death from melanoma. Individual tickets are $300 and may be purchased by visiting curemelanoma.thankyou4caring.org/LFFM2014.
“The fight against melanoma is ongoing, and every year there’s progress being made in both raising awareness and developing better treatments,” said Jeff Rowbottom. “MRA’s goal is to stop this disease in its tracks, and this event will raise funds to help the organization accelerate exciting developments in the area of cancer immunotherapy—using a person’s own immune system to fight melanoma. What we have learned through melanoma research is now being used to fight other cancers as well.”
Funds raised from the 2013 event were used for the LFFM-MRA Academic Industry Partnership Award, which supported investigators at Memorial Sloan Kettering and Johns Hopkins working on the combination of two cutting-edge immunotherapy cancer treatments, anti-CTLA-4 and anti-PD-1.
Nearly 80,000 Americans were diagnosed with melanoma in 2013—one person every eight minutes. It is the third most common cancer diagnosed in young people aged 15-39. If detected early, melanoma is often treatable, but people diagnosed with late-stage melanoma still face a grim prognosis. There is an urgent need for further research into better methods of preventing, diagnosing, and treating the disease.
In support of the 2014 event, a group led by the market intelligence and technology firm Ipreo and select LFFM donors has issued a $250,000 skin check challenge that provides $100 to MRA for every person who signs the skin check pledge. In order to sign the pledge, a person must have received a skin check in the last six months or pledge to make an appointment within the next six months. Individuals can sign the pledge at http://www.debtdomain.com/LFFM.
About The Melanoma Research Alliance (MRA)
MRA is a public charity formed in 2007 under the auspices of the Milken Institute, with the generous founding support of Debra and Leon Black. MRA has dedicated more than $60 million to research seeking to better prevent, diagnose, and treat melanoma. Due to the ongoing support of its founders, 100% of every dollar MRA raises goes to support its melanoma research program. The organization is poised to build on recent momentum in the field, accelerating the pace of scientific discovery and translation in order to eliminate suffering and death due to melanoma. MRA’s ability to fund wide-ranging research in melanoma is amplified by unique multi-faceted collaborations and partnerships with individuals, private foundations and corporations.
For more information on MRA, please visit www.CureMelanoma.org.